FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

raogco,	D.O. 200 .0	

OMB APPROVAL

3235-0287
e burden
se: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* <u>Sniecinski Megan</u>					2. Issuer Name and Ticker or Trading Symbol BIOCRYST PHARMACEUTICALS INC BCRX						5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner				
(Last) (First) (Middle) 4505 EMPEROR BOULEVARD SUITE 200				1	3. Date of Earliest Transaction (Month/Day/Year) 12/17/2019						X Officer (give title Other (specify below) Chief Business Officer				
(Street) DURHA			27703		. If Amo .2/19/2	,	ate of (Original Filed	l (Month/Day	/Year)	6. Ind Line)	Form file	ed by One Re	ng (Check App porting Persor an One Repor	1
(City)	(S	State)	(Zip)		÷ C		A	inad Di		D		0			
1. Title of Security (Instr. 3) 2. Tr. Date (Mor			Transact te onth/Day	Execution Date, if any (Month/Day/Year) Transaction Code (Instr. 8) Disposed Of (D) (Instr. 3, 4		Price	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)		Ownership rm: Direct) or Indirect (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	(e.g. 3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		options, 6. Date Exerc Expiration D (Month/Day/	cisable and	sable and te of Securities Underlying Derivative Section (Instr. 3 and 4) Expiration 7. Title and Am of Securities Underlying Derivative Section Am or Nur		8. Price of Derivative Security (Instr. 5) Benefic Owned Followin Reporte Transac (Instr. 4)		Ownership Form: Direct (D) or Indirect (I) (Instr. 4	Beneficial Ownership (Instr. 4)	
Emp. Stock Option (Right to Buy)	\$3.23	12/17/2019		A		240,000 ⁽¹⁾		12/17/2020	12/17/2029	Common Stock	240,000	\$0	240,000	D	

Explanation of Responses:

1. Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant.

/s/ Alane P. Barnes, by power of <u>attorney</u>

12/26/2019

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.